Quoin Pharmaceuticals Ltd. (QNRX) reports news about a late clinical-stage specialty pharmaceutical company developing therapies for rare and orphan diseases. Updates center on QRX003 lotion for Netherton Syndrome and related rare skin disorders, including clinical-study progress and U.S. and European orphan, rare pediatric disease and fast track regulatory designations.
Company news also covers QRX009 topical rapamycin development programs, rare dermatologic and genetic disease research, quarterly financial results, private-placement financing and distribution or commercialization arrangements for potential international markets.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its third quarter 2022 financial results on November 10, 2022, before the market opens. Management will conduct a webcast and conference call at 8:30 a.m. ET on the same day to discuss the results and corporate updates. The dial-in numbers for the call are 1-877-270-2148 (domestic) and 1-412-902-6510 (international). Quoin focuses on developing therapeutics for rare and orphan diseases, with a pipeline targeting conditions like Netherton Syndrome and Epidermolysis Bullosa.
Quoin Pharmaceuticals Ltd. announces the initiation of a multicenter, open-label clinical trial assessing QRX003 topical lotion in patients with Netherton Syndrome currently receiving systemic biologic therapy. Conducted under an existing U.S. IND Application, the study will take place over 12 weeks, aiming to evaluate safety and efficacy. QRX003, a broad-spectrum serine protease inhibitor, targets skin kallikreins to enhance skin barrier function. There are currently no approved therapies for Netherton Syndrome, making this trial crucial for developing new treatment options.
Quoin Pharmaceuticals Ltd. has opened three clinical sites for its study of QRX003, a treatment for Netherton Syndrome, a rare skin condition. The double-blind, placebo-controlled trial began in June 2022 and aims to recruit patients across six sites in the US, with the remaining three expected to open soon. QRX003, if approved, could be the first treatment for this condition. Quoin plans to self-commercialize QRX003 and has formed marketing partnerships in 60 countries, enabling potential early access.
Quoin Pharmaceuticals Ltd. (QNRX) initiated a clinical trial for its lead product QRX003, aimed at treating Netherton Syndrome, and expanded its global partnerships to eight across 60 countries. The company closed a $16.8 million public offering, netting approximately $15 million. Despite a net loss of $2.7 million for Q2 2022, Quoin regained compliance with Nasdaq's listing requirements concerning stockholders’ equity and minimum bid price. Significant progress includes a research agreement with Queensland University of Technology for scleroderma treatment.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its second quarter 2022 financial results on August 18, 2022, prior to market open. Management will host a webcast and conference call at 8:30 a.m. ET the same day to discuss the results and provide a corporate update. The live call can be accessed via specific domestic and international dialing codes, and the archived webcast will be available on the company's website. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline targeting multiple indications.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has closed its public offering of 11,050,000,000 ordinary shares, which equates to 2,210,000 American Depositary Shares (ADS) at $5.00 per ADS, alongside pre-funded warrants for 5,750,000,000 ordinary shares at $4.9999 each, generating $16.8 million in gross proceeds. The net proceeds will be utilized for general corporate purposes. The offering was facilitated by A.G.P./Alliance Global Partners, and the registration statement was approved by the SEC on August 5, 2022.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has priced a public offering of 2,210,000 American Depositary Shares (ADS) representing 11,050,000,000 ordinary shares at $5.00 per ADS, along with pre-funded warrants for 1,150,000 ADS at $4.9999 each. The total gross proceeds from the offering are expected to be $16.8 million, closing around August 9, 2022. Proceeds will be utilized for general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent for this offering, which follows an effective registration statement filed with the SEC.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it received significant Scientific Advice from the European Medicines Agency (EMA) regarding its product, QRX003, for treating Netherton Syndrome. This guidance, delivered sooner than expected, will enhance the clinical development plan in both the US and Europe. Currently in a clinical study in the US, QRX003 aims to improve the skin barrier for Netherton patients. The company has also expanded its distribution network to 60 countries, emphasizing accessibility for patients post-approval.
Quoin Pharmaceuticals (NASDAQ: QNRX) has signed a License and Distribution Agreement with Endo Ventures, an affiliate of Endo International for its lead product, QRX003, aimed at treating Netherton Syndrome, in Canada. Paladin Labs, a subsidiary of Endo, will handle commercialization upon regulatory approval. This marks Quoin’s eighth agreement for QRX003, expanding its market presence to 60 countries. CEO Dr. Michael Myers expressed optimism about the partnership's potential to enhance patient access to Quoin's products once approved.
Endo International plc (NASDAQ: ENDP) announced a collaboration with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) to develop and commercialize QRX003 for treating Netherton syndrome in Canada. This skin disorder, caused by a mutation in the SPINK5 gene, currently lacks effective treatment options. If approved, Paladin Labs, a subsidiary of Endo, will manage all commercial activities in Canada, aiming for a product launch in 2025. This partnership underscores Endo's focus on addressing unmet medical needs in rare diseases.